The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In the UK, people living with certain types of dementia, can be prescribed treatments to help manage their symptoms. These are known as symptomatic treatments. They include donepezil (part of a family ...

These are known as disease-modifying treatments. One of these, lecanemab, has been licensed for private use. Other medications are under review to see if they could be prescribed to people in the very ...

Pleurisy, which is inflammation in the lining of your lungs (pleura) that causes pain when you breathe, doesn't always need treatment. But you should always see a doctor if you have chest pain ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Most patients need treatments lasting a few minutes each 2-3 times per week for about 12 weeks. Considering that there might be travel costs and time off work required to visit a clinic ...

“Patients sometimes tell me that they ‘hear bad things’ about [ED treatments],” Dr. Gross told The Post. “These medications are among the most broadly prescribed drugs of the last ...

The first approval is for use with carboplatin and paclitaxel as a first-line treatment for adults with primary advanced or recurrent endometrial carcinoma who are eligible for systemic therapy. The ...

and is typically viewed as a "best-in-class" treatment option in most of its indications. Keytruda's patents are due to expire in 2028, however, at which point generic versions of the drug will be ...